Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580278 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
A Phase 1 study of Psoriasis, sponsored by Affibody.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03580278 is a Phase 1 study of Psoriasis that has completed, run by Affibody. The registered enrollment target is 33 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03580278, a Phase 1 study of Psoriasis, has completed, sponsored by Affibody.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.
Conditions Studied
Interventions
- BIOLOGICAL ABY-035/AFO2
Study Locations (1)
California
- Raoof, Joseph - Encino
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580278
The ClinicalTrials.gov registry entry for NCT03580278 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (93% lower). The listed sponsor is Affibody, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ABY-035/AFO2 is the first listed.
NCT03580278 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03580278 about?
NCT03580278 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2". The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.
What is the current status of trial NCT03580278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2019-11-13. Estimated completion is 2020-09-22.
What conditions does trial NCT03580278 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03580278?
The interventions under investigation include: ABY-035/AFO2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03580278?
This trial is sponsored by Affibody, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03580278 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.